Weekly Recap: IMVT-1402 halted for cutaneous lupus and FcRn programs
Roivant Sciences Ltd. (NASDAQ:ROIV) halted IMVT-1402’s cutaneous lupus program after a 12-week trial missed its primary endpoint, sending shares lower, while refocusing the asset on other autoimmune uses and prioritizing commercialization of FcRn programs for Graves' disease and uveitis.Previous We…